1. Home
  2. STOK vs JMIA Comparison

STOK vs JMIA Comparison

Compare STOK & JMIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STOK
  • JMIA
  • Stock Information
  • Founded
  • STOK 2014
  • JMIA 2012
  • Country
  • STOK United States
  • JMIA Germany
  • Employees
  • STOK N/A
  • JMIA N/A
  • Industry
  • STOK Biotechnology: Pharmaceutical Preparations
  • JMIA Catalog/Specialty Distribution
  • Sector
  • STOK Health Care
  • JMIA Consumer Discretionary
  • Exchange
  • STOK Nasdaq
  • JMIA Nasdaq
  • Market Cap
  • STOK 1.3B
  • JMIA 1.2B
  • IPO Year
  • STOK 2019
  • JMIA 2019
  • Fundamental
  • Price
  • STOK $22.74
  • JMIA $11.88
  • Analyst Decision
  • STOK Strong Buy
  • JMIA Buy
  • Analyst Count
  • STOK 6
  • JMIA 1
  • Target Price
  • STOK $26.60
  • JMIA $15.00
  • AVG Volume (30 Days)
  • STOK 893.3K
  • JMIA 4.5M
  • Earning Date
  • STOK 11-04-2025
  • JMIA 11-06-2025
  • Dividend Yield
  • STOK N/A
  • JMIA N/A
  • EPS Growth
  • STOK N/A
  • JMIA N/A
  • EPS
  • STOK 0.91
  • JMIA N/A
  • Revenue
  • STOK $199,893,000.00
  • JMIA $164,022,000.00
  • Revenue This Year
  • STOK $416.54
  • JMIA $21.44
  • Revenue Next Year
  • STOK N/A
  • JMIA $11.57
  • P/E Ratio
  • STOK $25.02
  • JMIA N/A
  • Revenue Growth
  • STOK 1218.82
  • JMIA N/A
  • 52 Week Low
  • STOK $5.35
  • JMIA $1.60
  • 52 Week High
  • STOK $24.60
  • JMIA $12.37
  • Technical
  • Relative Strength Index (RSI)
  • STOK 73.55
  • JMIA 76.09
  • Support Level
  • STOK $18.80
  • JMIA $9.52
  • Resistance Level
  • STOK $24.60
  • JMIA $12.37
  • Average True Range (ATR)
  • STOK 1.23
  • JMIA 0.65
  • MACD
  • STOK 0.02
  • JMIA 0.20
  • Stochastic Oscillator
  • STOK 67.93
  • JMIA 89.26

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

About JMIA Jumia Technologies AG each representing two

Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.

Share on Social Networks: